Hepatic histology of IBD patients following one year of combination therapy with allopurinol and low-dose conventional thiopurines

Hepatic histology of IBD patients following one year of combination therapy with allopurinol and low-dose conventional thiopurines - 1 years NRH of allopurinol and AZA/6MP

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37756

Enrollment

Registered

2012-04-04

Start date

2012-06-21

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatotoxicity liver injury

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Combination therapy of allopurinol and low dose thiopurine therapy for more than 1 year Crohn's disease or ulcerative colitis Adult patients

Exclusion criteria

Exclusion criteria: Anaemia (Hb

Design outcomes

Primary

Measure	Time frame
Histological assessed nodular regenerative hyperplasia of the liver	—

Secondary

Measure	Time frame
Histological changes after at least 1 year of combination therapy of allopurinol and low dose azathioprine and 6-mercaptopurine Endosonographically determined liver and spleen size and liver appearance Standard laboratory variables, including liver tests and full blood count Thiopurine metabolites: 6-TGN and 6-MMP determined in erythrocytes	—

Countries

Netherlands

Outcome results